SC moots regulatory body to monitor online content, observes everything cannot be allowed without accountability

The Centre informed the Supreme Court that it is in the final stages of putting together a regulatory framework for keeping a ...
New Jersey Business Magazine

Novartis Receives FDA Approval for Spinal Muscular Atrophy Gene Replacement Therapy

The FDA has approved Itvisma for the treatment of children two years and older, teens and adults living with spinal muscular ...

NYC wannabe influencer under fire over death of woman’s beloved dog — whose rotting corpse she packed into suitcase

I used to have a crate here for JC. For the first two months [after his death], I would carry this pillow and stay in the ...
Managed Healthcare Executive

FDA approves $2.59 million gene therapy for SMA

The FDA has approved Itvisma (onasemnogene abeparvovec-brve) to treat children two years and older, teens, and adults living with spinal muscular atrophy (SMA). It is indicated for patients with a ...

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults

Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function ...

Novartis Drug for Spinal Muscular Atrophy Gets FDA Approval

Novartis secured approval for its drug to treat certain patients diagnosed with spinal muscular atrophy from the Food and Drug Administration.

Novartis receives FDA approval for Itvisma(R), the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

ITVISMA is a prescription gene therapy used to treat adults and children 2 years of age and older with spinal muscular atrophy (SMA). ITVISMA is given as a one-time intrathecal injection. What is the ...

Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy

ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...